As a follow up to our post regarding Zohydro, a pure formulation of hydrocodone, this article explains the potential benefits of “the first single-entity hydrocodone” treatment.
Current prescribed formulations of hydrocodone typically contain other non-opioid compounds like acetaminophen or ibuprofen, both often added to discourage recreational use. However, oversuse of acetaminophen is the most common cause of acute liver damage in the United States. In addition, the FDA recently recommended limiting the dose of acetaminophen to 325 mg in combined prescription products
Potential Benefits of New Hydrocodone Formulation Seen in Clinical Trial
